The biotech sector sustains robust funding activity with major financing rounds and strategic licenses advancing oncology drug development. Congruence Therapeutics secured $32 million for protein misfolding disease candidates. Octave Bioscience closed a $35.6 million Series C to expand neurodegenerative disease diagnostics. Novartis inked a multi-asset deal worth up to $5.2 billion for Argo Biopharma's siRNA cardiovascular assets, strengthening RNA therapy pipelines. Braveheart Bio licensed Hengrui’s hypertrophic cardiomyopathy drug candidate for over $1 billion, targeting markets outside China. These investments reflect continued momentum in precision medicine and innovative cancer therapies.